Range Cancer Therapeutics ETF's Range Cancer Therapeutics ETF (CNCR) has disclosed 75 total holdings in their latest N-PORT filing with the SEC for the
portfolio date of 2024-08-31. The current portfolio value is calculated to be $13.00 Mil, only including common equities, preferred
equities, ETFs, options and warrants for equities. The turnover rate is 0%.
Range Cancer Therapeutics ETF (CNCR)'s
Total Assets is $13.27 Mil , Total Liabilities is $8,910.00 , Net Assets is $13.26 Mil.
In Range Cancer Therapeutics ETF (CNCR)'s current portfolio as of 2024-08-31, the top 5 holdings are
Summit Therapeutics Inc (SMMT), Geron Corp (GERN), Enliven Therapeutics Inc (ELVN), Acrivon Therapeutics Inc (ACRV) and Nurix Therapeutics Inc (NRIX),
not including call and put options.
Range Cancer Therapeutics ETF (CNCR) did not buy any new stocks in the current portfolio.
Please visit the "Current Portfolio" tab to see the ETF's current and past N-PORT holdings for Range Cancer Therapeutics ETF (CNCR), as well as holding map,
valuations for each stock, which positions are undervalued, have low PE Ratios, are considered high quality and recently traded at 52-week lows, etc.
Please visit the "Stock Picks" tab to see the ETF's latest trades and stock picks for Range Cancer Therapeutics ETF (CNCR), which include data from form N-PORT.
Please visit the "Summary" page to see the top 10 holdings, recent stock picks, performance, sector / industry breakdown details, as well as past holding history summary for Range Cancer Therapeutics ETF.